Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome
- 1 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 32 (1) , 22-28
- https://doi.org/10.1097/01.mpa.0000188305.90290.50
Abstract
An impaired host immunity might concur in determining the dismal prognosis of patients with pancreatic cancer (PC). Our aim was to ascertain whether the immunophenotype pattern of blood lymphocytes in PC correlates with tumor stage, grade, or survival. We studied 115 patients with PC, 44 with chronic pancreatitis (CP), 23 with tumors of the pancreatico-biliary tract, and 34 healthy controls (CS). Survival data were available for 77 patients with PC. Lymphocyte subsets were determined by fluorescent activated cell sorter (FACS) analysis. In patients with PC, total lymphocyte counts were lower than in CP or CS, and CD8+ lymphocyte subset levels were higher with respect to CS. Lower circulating lymphocytes were found in advanced PC stages (IIB-IV; χ2 = 11.55, P P The reduction of total lymphocytes in blood is the main immunologic change in advanced PC. The survival of these patients depends mainly on tumor stage, but it is also affected by the number of circulating lymphocytes, suggesting that the immune system plays an important role in pancreatic adenocarcinoma immunosurveillance and immunoediting.Keywords
This publication has 36 references indexed in Scilit:
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004
- Escape from immunotherapy: possible mechanisms that influence tumor regression/progressionCancer Immunology, Immunotherapy, 2004
- The genetics of pancreatic cancerThe American Journal of Surgery, 2003
- Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreasJournal of Gastrointestinal Surgery, 2003
- Immune responses in cancerPharmacology & Therapeutics, 2003
- Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative CareThe Oncologist, 2003
- Pancreatic cancer biology and geneticsNature Reviews Cancer, 2002
- Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group studyAnnals of Oncology, 2002
- Genetic basis of pancreatic cancerBest Practice & Research Clinical Gastroenterology, 2002
- Definitive Results of a Phase II Trial of Cisplatin, Epirubicin, Continuous-Infusion Fluorouracil, and Gemcitabine in Stage IV Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2001